Pascale Witz Appointed as Chair of Augustine Therapeutics
Augustine Therapeutics NV is making notable strides in the biotechnology arena with the recent appointment of Pascale Witz as the Chair of its Board of Directors. This significant change comes as Augustine intensifies its focus on creating innovative therapies to address neuromuscular and neurodegenerative diseases. Witz brings over three decades of experience in the life sciences sector, empowering Augustine as it transitions into a clinical-stage entity.
Experience of Pascale Witz
Pascale Witz is recognized for her impressive career in the life sciences industry, having served in key executive roles, including as Executive Vice President at Sanofi SA and CEO at GE Pharmaceutical Diagnostics. Her wealth of leadership experience is expected to play a pivotal role as Augustine aims to streamline its operations and enhance its research concentration on critical health issues. Her extensive background equips her with the insights needed to provoke growth and innovation within Augustine.
Comments from Augustine’s Leadership
Gerhard Koenig, PhD, CEO of Augustine Therapeutics, expressed enthusiasm about Witz joining the team. He stated that her prior collaboration with companies around therapeutic innovations has laid the foundation of trust and vision necessary for advancing Augustine’s mission. Koenig emphasized that Witz’s leadership is invaluable during this transformative phase for the company.
Strategic Growth Ahead
With Witz’s appointment following Augustine's successful financing round of €78 million (approximately $85 million), the company is poised for strategic growth. The funding reflects strong investor confidence in Augustine's innovative approach to developing HDAC6 inhibitors, which are seen as promising therapies in the treatment of neurodegenerative and cardio-metabolic diseases.
Witz's Vision for Augustine
Pascale Witz expressed her excitement about joining Augustine at such a crucial juncture. She aims to leverage her experience to guide the board and the company towards achieving its strategic goals. Her focus will be on maximizing the therapeutic potential of the HDAC6 inhibitors to lead to effective treatment solutions for patients living with significant healthcare challenges.
Pascale's Contribution Beyond Augustine
In addition to her role at Augustine, Witz contributes her expertise as a board member for various organizations such as Fresenius Medical Care AG, Revvity, Inc., and Regulus Therapeutics, Inc. Her involvement in these boards illustrates her commitment to furthering healthcare innovation and ensuring that effective governance practices are in place at these institutions.
Recognitions and Academic Background
Pascale holds a Master’s degree in Biochemistry and an MBA from the highly regarded INSEAD business school. Additionally, her outstanding contributions to the industry have earned her prestigious accolades, including the title of Chevalier de la Légion d’Honneur and recognition among Fortune’s Top 20 Most Powerful Women in EMEA in consecutive years.
About Augustine Therapeutics
Augustine Therapeutics specializes in the development of next-generation therapies targeting neuromuscular and neurodegenerative disorders. The company’s lead program, AGT-100216, represents a groundbreaking advancement as the first selective HDAC6 inhibitor aimed at treating Charcot-Marie-Tooth (CMT) disease. Augustine employs innovative methodologies to ensure that these therapies effectively target disease processes while minimizing side effects. Additionally, with aspirations to extend beyond CMT treatments, Augustine is committed to enhancing the lives of patients battling a variety of health concerns.
Frequently Asked Questions
Who is Pascale Witz?
Pascale Witz is a seasoned executive appointed as Chair of Augustine Therapeutics' Board of Directors, with over 30 years of experience in the life sciences industry.
What is the main focus of Augustine Therapeutics?
Augustine Therapeutics focuses on developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases through HDAC6 inhibition.
What recent funding did Augustine Therapeutics secure?
Augustine Therapeutics has recently secured €78 million ($85 million) in funding to support its innovative research and development efforts.
What is the significance of HDAC6 inhibitors?
HDAC6 inhibitors have the potential to treat various diseases by modulating key cellular processes associated with neurodegenerative and cardio-metabolic conditions.
What accolades has Pascale Witz received?
Pascale Witz is recognized as Chevalier de la Légion d’Honneur and featured among Fortune’s Top 20 Most Powerful Women in EMEA in 2014 and 2015.
